Called “game-changing” in the World Nobel Prize Laureate Summit on Biomedical Science (NPLS) publications, Anpac Bio’s CDA technology and proprietary medical devices effectively reinvent early cancer screening and detection.
By analyzing simple, in vitro, “Blood Biopsies” and applying Anpac Bio’s proprietary, multi-level multi-parameter screening algorithms, CDA technology and testing identify cancer and other diseases with measurably greater sensitivity, specificity, and accuracy than most current, conventional screening methods.
Anpac Bio’s proprietary Cancer Differentiation Analysis (CDA) technology:
• Detects over 26 different types of cancer in all stages of development—often identifying cancer at its earliest stages
• Helps physicians identify the disease and best treatment options by distinguishing the cancer’s likely location in the body
• Is far more accurate than other, traditional cancer testing, with an 85%-90% sensitivity and specificity, respectively (in 200,000 cases served to date)
• Has screened out >525 cases of pre- and stage I cancer, as well as diseases which may lead to cancer, typically NOT screened out using current cancer screening technologies.